Dr. Julie M. Cherrington, PhD is a life science executive with extensive experience bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA approved products, including SUTENT™, Palladia™, Vistide™, Viread™, and Hepsera™.
Julie is currently the President and CEO of Arch Oncology, an immune-oncology company developing novel anti-CD47 mAbs. From 2015 to 2017, Julie served as President and CEO of Revitope, Inc an immuno-oncology company. Julie served as President and CEO of Zenith Epigenetics, a clinical stage company developing BET inhibitors, from 2014 to 2015. From 2009 to 2014, Julie was President and CEO of Pathway Therapeutics, a clinical stage company advancing targeted kinase inhibitors for the treatment of cancer. Prior to joining Pathway, she served as President and EVP R&D of Phenomix Corporation. Prior to joining Phenomix in 2003, Julie was vice president of preclinical and clinical research at SUGEN, a Pharmacia/Pfizer company. Julie began her career at Gilead Sciences where she held a range of positions of increasing responsibility.
Julie has served on the Boards of Directors of Chemgenex, Progen, Xenome, and Leading Biosciences. She is currently a member of the Scientific Advisory Board of the Clearity Foundation and is an advisor in entrepreneurship initiatives at CLSI, UC San Francisco, and UC Davis.